Kasimu Hussaini: Blood Component Therapy From Whole Blood to Targeted Treatment
Kasimu Hussaini, Medical Laboratory Technician Student Clinical Practicum at General Hospital kaura Namoda, shared a post on LinkedIn:
”Understanding Blood Component Therapy: From Whole Blood to Targeted Components
Blood transfusion medicine is not simply about giving blood—it is about giving the right component to the right patient for the right clinical indication.
Through component separation, one blood donation can provide different therapeutic products, helping to meet specific patient needs.
Packed Red Blood Cells (PRBCs)
Used primarily to increase oxygen-carrying capacity in patients with significant anemia or blood loss.
Platelet Concentrates
Used for thrombocytopenia, platelet dysfunction, and bleeding associated with inadequate platelet numbers or function.
Fresh Frozen Plasma (FFP)
Contains multiple coagulation factors and is used when clinically significant coagulation-factor deficiency requires plasma replacement.
Cryoprecipitate
Rich in fibrinogen and also contains factor VIII, factor XIII, and von Willebrand factor. It is particularly useful when fibrinogen replacement is required.
Whole Blood
Contains red cells, plasma, and platelets and may be used in selected cases of major hemorrhage or where component therapy is not appropriate or available.
Plasma-Derived Products
These include products such as albumin, immunoglobulins, and specific coagulation-factor concentrates, which are manufactured and purified for particular clinical indications.
The goal of component therapy is simple:
Give the patient what they need—not necessarily everything contained in whole blood.
This approach helps optimize transfusion therapy and makes the most effective use of every blood donation.
For laboratory scientists and transfusion practitioners:
Which blood component do you handle or crossmatch most frequently in your laboratory?”
Stay updated with Hemostasis Today.
-
Oct 25, 2026, 17:23Zahra Safarzadeh: When Low Factor VII Activity and Reduced VWF Antigen Coexist
-
Oct 25, 2026, 17:17Anubhav Joshi: Evans Syndrome in CLL A Differential Diagnosis to Remember
-
Oct 25, 2026, 17:04Tehila Alter: Tracking Hematopoietic Cell Engraftment in Bone Marrow Using CEST MRI
-
Oct 25, 2026, 16:45Shauna Riley։ First Guidelines for Hemoglobin SC Disease
-
Oct 25, 2026, 16:26Heghine Khachatryan: Patient Safety and Clinical Judgment in Platelet Transfusion Decisions
-
Oct 25, 2026, 16:13Funmi (Vanessa) Ullam: From Lived Experience to Research and Innovation in Sickle Cell Care
-
Oct 25, 2026, 15:13Franky Biles: Celebrating Diversity and Driving Inclusion Through Representation
-
Oct 25, 2026, 14:47Siddharth Mittal: A Sheet-Like Effluent Deposit During Plasma Exchange in iTTP
-
Oct 25, 2026, 14:16Alejandro González Veliz: Can Factor XIa Inhibition Prevent Recurrent Ischemic Events Without Increasing Bleeding?